{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:32:07Z","timestamp":1793406727149,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jhep.2023.06.002","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T01:01:32Z","timestamp":1687309292000},"page":"1254-1269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"title":["Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference"],"prefix":"10.1016","volume":"79","author":[{"given":"Marc G.","family":"Ghany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2023.06.002_bib1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B-report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"66","author":"Lok","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.06.002_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib4","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2022.11.020","article-title":"Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss","volume":"78","author":"Yip","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib5","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.06.002_bib6","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/0016-5085(87)90613-5","article-title":"Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection","volume":"92","author":"Lok","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.06.002_bib7","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/hep.30082","article-title":"Hepatitis B virus serum DNA and RNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection","volume":"68","author":"Butler","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.06.002_bib8","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hep.26385","article-title":"Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles","volume":"58","author":"Lee","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.06.002_bib9","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastro- enterology"},{"issue":"S1","key":"10.1016\/j.jhep.2023.06.002_bib10","first-page":"19","article-title":"SLAAe. Preliminary 48-week safety and efficacy data of VIR-2218 alone and in combination with pegylated interferon alfa in participants with chronic HBV infection","volume":"76","author":"Yuen","year":"2022","journal-title":"Abstracts. Hepatology"},{"key":"10.1016\/j.jhep.2023.06.002_bib11","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of Bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N Engl J Med"},{"issue":"S1","key":"10.1016\/j.jhep.2023.06.002_bib12","first-page":"5012","article-title":"Efficacy and safety of combination treatment with siRNA JNJ-73763989 and capsid assembly modulator JNJ-56136379 (bersacapavir) in HBeAg negative virologically suppressed chronic hepatitis B patients: follow-up week 48 end of study results from REEF-2","volume":"76","author":"Agarwal","year":"2022","journal-title":"Abstr Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib13","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.06.002_bib14","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.cgh.2019.07.018","article-title":"Durability of spontaneous and treatment-related loss of hepatitis B s antigen","volume":"18","author":"Alawad","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib15","article-title":"Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients","author":"Yip","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2023.06.002_bib17","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.06.002_bib18","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib19","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cgh.2013.01.026","article-title":"Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency","volume":"11","author":"Wong","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib20","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2021.12.286","article-title":"Inhibition of viral replication reduces transcriptionally active distinct hepatitis B virus integrations with implications on host gene dysregulation","volume":"162","author":"Hsu","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.06.002_bib21","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1093\/cid\/ciac383","article-title":"Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion","volume":"76","author":"Chow","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2023.06.002_bib22","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","article-title":"Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB","volume":"77","author":"Yuen","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib23","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2022.05.027","article-title":"Safety and efficacy of vebicorvir administered with entecavir in treatment-naive patients with chronic hepatitis B virus infection","volume":"77","author":"Sulkowski","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib24","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2022.04.005","article-title":"Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection","volume":"77","author":"Yuen","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib25","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S0168-8278(20)30773-X","article-title":"Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: interim week 24 data","volume":"73","author":"Janssen","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","article-title":"Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues","volume":"143","author":"Boni","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.06.002_bib27","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","article-title":"Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection","volume":"67","author":"Murata","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.06.002_bib28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients","volume":"15","author":"Kao","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2023.06.002_bib29","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib30","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)","volume":"68","author":"Liem","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.06.002_bib31","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep4.1708","article-title":"Risks and benefits of discontinuation of nucleos(t)ide analogue treatment: A treatment concept for patients with HBeAg-negative chronic hepatitis B","volume":"5","author":"van Bommel","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2023.06.002_bib32","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.cgh.2020.04.037","article-title":"Incidence and factors associated with HBV relapse after cessation of entecavir or tenofovir in patients with HBsAg below 100 IU\/mL","volume":"18","author":"Tseng","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib33","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.06.002_bib34","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s12072-020-10099-x","article-title":"Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2023.06.002_bib35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.06.002_bib36","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1128\/AAC.00249-15","article-title":"Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2023.06.002_bib37","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","article-title":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)","volume":"61","author":"Ning","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib38","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jcv.2013.09.020","article-title":"Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs","volume":"58","author":"Ouzan","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jhep.2023.06.002_bib39","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1016\/j.cgh.2021.04.031","article-title":"Switching to or add-on peginterferon in patients on nucleos(t)ide analogues for chronic hepatitis B: The SWAP RCT","volume":"20","author":"Lim","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib40","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naive to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.06.002_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2023.06.002_bib42","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.gastro.2017.10.017","article-title":"Efficacy of NVR 3-778, alone and in combination with pegylated interferon, vs entecavir in uPA\/SCID mice with humanized livers and HBV infection","volume":"154","author":"Klumpp","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.06.002_bib43","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","article-title":"Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection","volume":"156","author":"Yuen","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.06.002_bib44","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2020-322571","article-title":"Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5\/6 complex and silencing of the viral genome in vivo","volume":"71","author":"Allweiss","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.06.002_bib45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","article-title":"End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB","volume":"77","author":"Huang","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba6322","article-title":"Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection","volume":"13","author":"Nishio","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2023.06.002_bib47","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2022.03.006","article-title":"A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV \u201ccure\u201d","volume":"77","author":"Agarwal","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib48","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000002176","article-title":"Withdrawal of long-term nucleotide analogue therapy in chronic hepatitis B: Outcomes from the withdrawal phase of the HBRN immune active treatment trial","author":"Feld","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2023.06.002_bib49","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2014.01.044","article-title":"Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA","volume":"146","author":"Chan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.06.002_bib50","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.30417","article-title":"Entecavir and peginterferon alfa-2a in adults with hepatitis B e antigen-positive immune-tolerant chronic hepatitis B virus infection","volume":"69","author":"Feld","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.06.002_bib51","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1136\/gutjnl-2021-324646","article-title":"Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection","volume":"71","author":"Aliabadi","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2023.06.002_bib52","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","article-title":"Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels","volume":"116","author":"Chu","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2023.06.002_bib53","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12072-007-9002-9","article-title":"Spontaneous relapse of hepatitis in inactive HBsAg carriers","volume":"1","author":"Chu","year":"2007","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2023.06.002_bib54","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.cgh.2020.04.091","article-title":"Should treatment indications for chronic hepatitis B be expanded?","volume":"19","author":"Jeng","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib55","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/liv.13416","article-title":"Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance","volume":"37","author":"Oliveri","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.06.002_bib56","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive designs for clinical trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2023.06.002_bib57","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/jvh.13366","article-title":"Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta","volume":"27","author":"Wranke","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2023.06.002_bib58","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/infdis\/jix656","article-title":"Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease","volume":"217","author":"Yurdaydin","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2023.06.002_bib59","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.28876","article-title":"Antiviral treatment and liver-related complications in hepatitis delta","volume":"65","author":"Wranke","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.06.002_bib60","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2023.06.002_bib61","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/jvh.13439","article-title":"A transient early HBV-DNA increase during PEG-IFNalpha therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction","volume":"28","author":"Anastasiou","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2023.06.002_bib62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.06.002_bib63","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2018.12.022","article-title":"Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy","volume":"70","author":"Yurdaydin","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2023.06.002_bib65","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.06.002_bib66","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/apt.16485","article-title":"One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease","volume":"54","author":"Palom","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2023.06.002_bib67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/apt.16945","article-title":"Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a \u201creal world\u201d study","volume":"56","author":"Jachs","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"S1","key":"10.1016\/j.jhep.2023.06.002_bib68","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(22)00433-0","article-title":"Efficacy and safety of bulevirtide mono-therapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study","volume":"77","author":"Wedemeyer","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib69","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/liv.14171","article-title":"Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication","volume":"39","author":"Younossi","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.06.002_bib70","article-title":"Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B","volume":"3","author":"Buti","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2023.06.002_bib71","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.cgh.2018.02.037","article-title":"Effects of treatment of chronic hepatitis B virus infection on patient-reported outcomes","volume":"16","author":"Younossi","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.06.002_bib72","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/jvh.13451","article-title":"Development and validation of a hepatitis B-specific health-related quality-of-life instrument: CLDQ-HBV","volume":"28","author":"Younossi","year":"2021","journal-title":"J Viral Hepat"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823004178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823004178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:50:15Z","timestamp":1759175415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823004178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0168827823004178"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.06.002","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Association for the Study of Liver Diseases and European Association for the Study of the Liver. Published by Wolters Kluwer and Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}